HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Esmirtazapine

HCID 3085218
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
61337-87-9
Standard SMILES
CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
InChIKey
RONZAEMNMFQXRA-MRXNPFEDSA-N
Molecular formula
C17H19N3
Average molar mass
265.35 g/mol
Monoisotopic mass
265.15789762

Overview

Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology. This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors. Merck has terminated its internal clinical development program for esmirtazapine as of March 2010.

Names & identifiers

Preferred name
Esmirtazapine
IUPAC
(7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
English name
(S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
Molecular formula
C17H19N3
Molecular weight
265.35286

Names & synonyms

Esmirtazapine(S)-Mirtazapine61337-87-9(+)-Mirtazapine(s)-6-azamianserinMirtazapine, (s)-(s)-org 3770esmirtazapinaOrg-44-20(S)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine4685R51V7MDTXSID001029320
Show more names
(S)-Org3770D3-S-MirtazapineS-(+)-Mirtazapine(+)-(S)-Mirtazapine(S)-Mirtazapine-13C-d3Mirtazapine Impurity 23(S)Mirtazapine,(S) Mirtazapine
(S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepineesmirtazapinumRefChem:137870DTXCID901514590(7S)-5-methyl-2,5,19-triazatetracyclo(13.4.0.02,?.0?,13)nonadeca-1(15),8,10,12,16,18-hexaene262-714-0Esmirtazapine [INN](7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene

Database identifiers

CAS
61337-87-9

Properties

Computed structural propertiesFilling in

XLogP
3.3
Topological polar surface area
19.4 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
3
Rotatable bonds
0
Heavy atoms
20
Formal charge
0
Complexity
345

Experimental & physicochemical properties

SolubilitySoluble in methanol and chloroform mg/mL (20 °C)

Physicochemical properties

Melting point
85 · 85 - 87°C
storage temp.
-20 °C · -20°C Freezer
solubility
Chloroform (Slightly), Methanol (Slightly)
form
Solid
color
White to Off-White
FDA UNII
4685 R51V7M · 4685R51V7M

Chemistry & industry

Pharmacology

Biological Half-Life10 hours
MeSH Pharmacological Classification · 6 items

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Drugs that bind to and block the activation of ADRENERGIC ALPHA-2 RECEPTORS.

Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.

Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS.

Applications

UsesS-Mirtazapine is an enantiomer of Mirtazapine (M365000); an antidepressant. R-Mirtazapine showed antinociceptive effects in acute thermal nociception, whereas S-Mirtazapine showed pronociceptive effects.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes
PubChem CID
3085218
DTXSID
DTXSID001029320
ChEMBL
CHEMBL1366933
UNII
4685R51V7M
EC Number
262-714-0
Nikkaji
J279.597C